CURE RARE DISEASE PRESENTS
Covid-19 Vaccine's Impact on Gene Therapy
About the Webinar
What are neutralizing antibodies? How do NAbs impact gene therapy? How does the COVID vaccines impact AAV Nabs?Join Cure Rare Disease to hear about the Covid-19 Vaccine's impact on Gene Therapy. We will hear from featured experts in Neutralizing Antibodies on the effect the Covid-19 vaccine may have on the future of gene therapy featuring experts Dr. Federico Mingozzi and Dr. Noah Weisleder.
About the Speakers
Dr. Federico Mingozzi is the chief scientific officer at Spark Therapeutics, bringing two decades of experience in gene therapy, immunology, as well as biochemistry and molecular biology in both industry and academic settings. Federico was involved in several first-in-human clinical studies of gene therapy based on the AAV vector platform while serving as the director of translational research the Center for Cellular and Molecular Therapeutics, at CHOP. He also led studies aimed at the characterization of human immune responses to AAV vectors and the development of strategies to modulate vector immunogenicity. Throughout his distinguished career, Federico has received several awards and has contributed to the field of gene therapy with more than 100 scientific publications, including seminal findings in the field of AAV gene therapy.
Dr. Weisleder is Professor and Director of Graduate Studies in the Department of Physiology and Cell Biology at The Ohio State University Wexner Medical Center. He has published numerous peer-reviewed publications or book chapters in the fields of muscle physiology, cardiovascular disease, cytoskeletal dynamics, membrane repair, and cellular calcium homeostasis in normal physiology and disease states, many of which focused on muscular dystrophies and other myopathies. He has received a wide variety of awards that include a fellowship from the American Heart Association, a Pathway to Independence Award from the NIH, and the Kauffman Foundation Outstanding Postdoctoral Entrepreneur Award. He has received a wide variety of awards that include a fellowship from the American Heart Association, a Pathway to Independence Award from the NIH, and the Kauffman Foundation Outstanding Postdoctoral Entrepreneur Award.
Federico Mingozzi, PhD. Chief Science Officer, Spark Therapeutics
Noah Weisleder, PhD. Professor and Director of Graduate Studies, The OSU Wexner Medical Center